Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Clin Cancer Res. 2012 Sep 13;18(21):5983–5991. doi: 10.1158/1078-0432.CCR-12-0774

Figure 1.

Figure 1

Kaplan–Meier estimates of the effect of selected SNPs on survival probability in never-smokers with lung cancer. A, IL17RA: rs879576 in the MD Anderson population (discovery phase). B, IL17RA:rs879576 in the Mayo Clinic population (validation phase). C, SYK:rs290229 in the MD Anderson population (discovery phase). D, SYK:rs290229 in the Mayo Clinic population (validation phase). E, BMP8A:rs698141 in the MD Anderson population (discovery phase). F, BMP8A:rs698141 in the Mayo Clinic (validation phase). G, CD74:rs1056400in the MD Anderson population (discovery phase). H, CD74:rs1056400 in the Mayo Clinic population (validation phase). I, CD38:rs10805347 in the MD Anderson population (discovery phase). J, CD38:rs10805347 in the Mayo Clinic population (validation phase). N = A/B, A: number of patients with event, B: total number of patients.